**Background**

- In 2017, led by a steering group of international multiple sclerosis (MS) specialists, the MS in the 21st Century initiative was formed.
- This group's remit was to determine the relevance of resources available to people with MS (PwMS).

**Objective**

- The mapping exercise aimed to better understand the diversity and number of patient educational materials available for PwMS across Europe and Canada by a broad range of stakeholders involved in the care and education of PwMS.
- This research model can be applied to other global regions.

**Methods**

- Educational resources in Europe and Canada were recorded using pre-defined mapping parameters (Figure 1).

**Results**

**Resource Review**

- From the 21 countries mapped, 1,657 different educational resources were identified across all stakeholders, which included websites and online pages, books, videos, and patient values.

**Resource Overall Theme**

- The highest single-country total was from the UK (322) (Figure 6).

**Resource Dissemination**

- Websites and online content were the most common formats, followed by brochures (leaflets). A total of 18 languages were used to produce educational and informational resources for PwMS, including 60% of the materials in English.

**Conclusions**

- This research demonstrated that there is a large offering of educational materials for PwMS for the type and number of multiple sclerosis (MS) centres across Europe and Canada.

**Acknowledgements**

The MS in the 21st Century initiative is financially supported by Merck KGaA, Darmstadt, Germany. Societal input was provided by Helen Hammond from iS Health. Medical writing assistance was provided by and was funded by Merck KGaA, Darmstadt, Germany.

**Disclosure**

Peter Rieckmann receives honoraria for lectures from: Astellas, Aprea, Astellas, Bayer, Biogen, Novartis, Merck, Medtronic, and Sanofi-Aventis. He receives research grants from: Aprea, Bayer, EMD Serono, Novartis, MS Society of Germany, Canadian Institutes of Health Research. His current affiliations include: iS Health, Astellas, Merck, Bayer, Novartis, and Sanofi-Aventis.